Studies have shown that FDX1 can inhibit the growth and progression of colorectal cancer by delaying the epithelial-mesenchymal transition (EMT) process (Wang et al., 2025), and its low expression is significantly correlated with poor prognosis in colorectal cancer patients ( Wang et al., 2023). The gene discussed is FDX1; the disease is colorectal cancer.